LONDON: Oncimmune Holdings plc has signed two separate agreements with Roche Pharmaceuticals and Cedars-Sinai Medical Center, in each case to use the company’s newly developed and proprietary Infectious Disease panel. On 6 October 2020, Oncimmune announced the award of UK Government funding for the development and validation of an Infectious Disease NavigAID panel under the…
LONDON: Oncimmune Holdings plc has signed a commercial agreement with Cedars-Sinai, California, USA, to provide antibody profiling in COVID-19 samples as biomarkers for this disease, a news release said. Oncimmune Holdings is being funded by the UK Government to develop a COVID-19 biomarker panel. Cedars-Sinai is a world-leading medical research organisation serving more than 1…
LONDON: Oncimmune Holdings announced the award of funding from the ‘UK Research and Innovation (UKRI) Ideas to Address COVID-19’ programme, to support a joint collaboration between Oncimmune and Medicines Discovery Catapult to deliver the IMmunity Profiling of pAtients with COVID-19 for Therapy and Triage (IMPACTT) programme. This collaboration represents a critical partnership in response to…